Abstract
Ischemic heart disease and myocardial infarction continue to be leading causes of cardiovascular morbidity and mortality. Activation of opioid, adenosine, bradykinin, adrenergic and other G-protein coupled receptors has been found to be cardioprotective. κ- and/or δ-opioid receptor activation is involved in direct myocardial protection, while the role of µ-opioid receptors seems less clear. In addition, differential affinities to the three opioid-receptor subtypes by various agonists and cross-talk among different G-protein coupled receptors render conclusions regarding opioid-mediated cardioprotection challenging. The present review will focus on the protective effects of endogenously released opioid peptides as well as exogenously administered opioids such as morphine, fentanyl, remifentanil, butorphanol, and methadone against myocardial ischemia/reperfusion injury. Receptor heterodimerization and cross-talk as well as interactions with other cardioprotective techniques will be discussed. Implications for opioid-induced cardioprotection in humans and for future drug development to improve myocardial salvage will be provided.
Keywords: Butorphanol, cross-talk, enkephalin, fentanyl, heterodimerization, ischemia-reperfusion injury, opioid receptors, methadone, morphine, myocardial, remifentanil.
Current Pharmaceutical Design
Title:Opioid-induced Cardioprotection
Volume: 20 Issue: 36
Author(s): Katsuya Tanaka, Judy R. Kersten and Matthias L. Riess
Affiliation:
Keywords: Butorphanol, cross-talk, enkephalin, fentanyl, heterodimerization, ischemia-reperfusion injury, opioid receptors, methadone, morphine, myocardial, remifentanil.
Abstract: Ischemic heart disease and myocardial infarction continue to be leading causes of cardiovascular morbidity and mortality. Activation of opioid, adenosine, bradykinin, adrenergic and other G-protein coupled receptors has been found to be cardioprotective. κ- and/or δ-opioid receptor activation is involved in direct myocardial protection, while the role of µ-opioid receptors seems less clear. In addition, differential affinities to the three opioid-receptor subtypes by various agonists and cross-talk among different G-protein coupled receptors render conclusions regarding opioid-mediated cardioprotection challenging. The present review will focus on the protective effects of endogenously released opioid peptides as well as exogenously administered opioids such as morphine, fentanyl, remifentanil, butorphanol, and methadone against myocardial ischemia/reperfusion injury. Receptor heterodimerization and cross-talk as well as interactions with other cardioprotective techniques will be discussed. Implications for opioid-induced cardioprotection in humans and for future drug development to improve myocardial salvage will be provided.
Export Options
About this article
Cite this article as:
Tanaka Katsuya, Kersten R. Judy and Riess L. Matthias, Opioid-induced Cardioprotection, Current Pharmaceutical Design 2014; 20 (36) . https://dx.doi.org/10.2174/1381612820666140204120311
DOI https://dx.doi.org/10.2174/1381612820666140204120311 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin Resistance-Induced Hypertension and a Role of Perivascular CGRPergic Nerves
Current Protein & Peptide Science PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol
Mini-Reviews in Medicinal Chemistry Screening Strategies to Identify New Antibiotics
Current Drug Targets The Mediterranean Diet and Gastrointestinal Cancers Risk
Recent Patents on Food, Nutrition & Agriculture Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design Induction of Cytoprotective Genes Through Nrf2 / Antioxidant Response Element Pathway: A New Therapeutic Approach for the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Editorial
Recent Patents on Food, Nutrition & Agriculture Synthetic Genomics and Synthetic Biology Applications Between Hopes and Concerns
Current Genomics Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research Natural Products Based Ayurvedic Formulations: Chemical Cons tituents and Treatment in Neurodegenerative Disordersǂ
Mini-Reviews in Organic Chemistry Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews Monitoring Cardiac Function During Idebenone Therapy in Friedreich's Ataxia
Current Pharmaceutical Design Can Edible Insects Complement Conventional Livestock? The Desirability of Insect Nutrition for Food Security of a World Heritage Site and Biosphere Reserve
Current Nutrition & Food Science Biomarkers in Atrial Fibrillation and Heart Failure
Current Medicinal Chemistry Iron Overload and Glucose Metabolism in Subjects with β-thalassaemia Major : An Overview
Current Diabetes Reviews Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design An Update on the Cardiovascular Effects of Quercetin, a Plant Flavonoid
Current Nutrition & Food Science Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Determination of Selenium in Eggs of Different Birds Using Sample Digestion in a Reflux System and Hydride Generation Atomic Fluorescence Spectrometry
Current Analytical Chemistry